Tianchen Biotech Secures Nearly RMB 100 Million in Series A+ Financing to Accelerate Development of Innovative Domestic Ophthalmic Devices

VCBeat has learned at the earliest opportunity that,Tianchen (Tianjin) Biotechnology Co., Ltd. (hereinafter referred to as “Tianchen Biotech”)Announced the completion of its nearly RMB 100 million Series A+ financing round. This round was led byChina Merchants InternationalLead investor; industrial investors participating as co-investors. The financing proceeds will be used for clinical trials of the pipeline under development and for industrialization infrastructure.

Tianchen Biologics is a company specializing in the research and development, manufacturing, and sales of Class III ophthalmic medical devices. With multidisciplinary teams in materials science, optics, and clinical ophthalmology, the company develops innovative medical devices that address unmet clinical needs in eye care. Its product portfolio includes both active and passive medical devices.

The company has established a presence in multiple regions, leveraging regional advantages for collaborative synergy. The Tianjin headquarters serves as the R&D center and the manufacturing hub for active medical devices; the Suzhou and Tianjin branches function as manufacturing centers for passive medical devices; and Nantong operates as the sales center for the full product line.

Glaucoma, myopia, and dry eye disease are the three most prevalent conditions in China’s ophthalmology sector. According to the “2022 Ophthalmology Industry Research Report” released by VCBeat, China has the world’s largest myopic population, reaching 630 million; the number of patients with dry eye disease has reached 360 million; and the number of glaucoma patients has also reached 50 million. With the deepening aging of China’s population and changes in modern lifestyles, the incidence of ophthalmic diseases will continue to rise, and treatment demand will increase significantly. As ophthalmology is the medical specialty most reliant on instruments and equipment,Tianchen Biotech has designed three distinct product lines targeting glaucoma, myopia, and dry eye disease, respectively, with each line comprising multiple products.

The glaucoma product line comprises multiple product types, capable of treating patients at all stages of glaucoma.Minimally Invasive Intraocular Implant, indicated for the treatment of patients with various types of glaucoma. The product demonstrates leading efficacy, excellent biocompatibility, a low incidence of postoperative adverse reactions, and favorable therapeutic outcomes. It is primarily used for patients with uncontrolled glaucoma.Non-invasive Therapeutic Device, coagulate the ciliary body to treat glaucoma.

The myopia product line features a world-first innovation.In Vivo Corneal Biomechanical Analyzer, an in vivo corneal biomechanics measurement device for preoperative screening of corneal biomechanics in myopia surgery to avoid serious postoperative complications. In terms of implants, there areFully Proprietary Patent Minimally Invasive Intraocular Implant for Artificial Lenses, used for correcting myopia.

In terms of the dry eye disease product line, Tianchen has two product lines: serious medical care and consumer medical care. The serious medical care segment mainly focuses onIntense Pulsed Light (IPL) Dry Eye Treatment Device,Use multi-wavelength pulsed light as a therapeutic modality to improve meibomian gland function and treat dry eye.Tianchen FMCG Series ProductsGiven the recurrent nature of dry eye disease, we emphasize the concepts of home-based and daily care, and design products targeting its pathogenesis to enhance therapeutic efficacy.

After years of development, the company has established partnerships withChinese PLA General Hospital, Beijing Tongren Hospital, Tianjin Eye Hospital, Tsinghua University, Sichuan University, Nankai University, Stanford University, Boston Eye Center...and deep collaborations with multiple top-tier hospitals and universities both in China and abroad.

Regarding securing this round of financing,Company Founder, Dr. Wustated: “We extend our sincere gratitude to CMB International and other industrial investors for their strong support. Guided by clinical needs and leveraging our proprietary theoretical validation models, we are innovating existing products to develop a comprehensive portfolio tailored to Chinese patients at all disease stages. We are committed to making contributions to the care of patients affected by the three major ophthalmic diseases.”

China Merchants Internationalstated: “We are highly optimistic about the ophthalmic healthcare sector, which combines attributes of both consumer healthcare and serious medical care. In particular, in areas with unmet clinical needs such as glaucoma and implantable intraocular lenses, Tianchen Bio has demonstrated strong R&D capabilities and resource integration abilities. We have also observed promising experimental results for its related products, which hold the potential to break the long-standing monopoly held by foreign competitors. We look forward to the early market launch of Tianchen Bio’s products to benefit patients.”